Truist Financial Corp Grows Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Truist Financial Corp lifted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 6.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,725 shares of the medical research company’s stock after purchasing an additional 2,281 shares during the period. Truist Financial Corp owned about 0.08% of Charles River Laboratories International worth $7,818,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Arizona State Retirement System raised its stake in Charles River Laboratories International by 0.3% during the 2nd quarter. Arizona State Retirement System now owns 14,090 shares of the medical research company’s stock worth $3,015,000 after acquiring an additional 43 shares in the last quarter. Wetherby Asset Management Inc. raised its stake in Charles River Laboratories International by 2.5% during the 1st quarter. Wetherby Asset Management Inc. now owns 1,793 shares of the medical research company’s stock worth $509,000 after acquiring an additional 44 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Charles River Laboratories International by 1.6% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,121 shares of the medical research company’s stock worth $668,000 after acquiring an additional 50 shares in the last quarter. Cardinal Capital Management raised its stake in Charles River Laboratories International by 0.7% during the 2nd quarter. Cardinal Capital Management now owns 7,717 shares of the medical research company’s stock worth $1,651,000 after acquiring an additional 53 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in Charles River Laboratories International by 4.0% during the 2nd quarter. Cetera Investment Advisers now owns 1,478 shares of the medical research company’s stock worth $316,000 after acquiring an additional 57 shares in the last quarter. 97.80% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 6,409 shares of the business’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $224.25, for a total transaction of $1,437,218.25. Following the sale, the executive vice president now owns 20,232 shares of the company’s stock, valued at $4,537,026. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 2,279 shares of the company’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $249.90, for a total value of $569,522.10. Following the sale, the executive vice president now owns 2,499 shares of the company’s stock, valued at $624,500.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph W. Laplume sold 6,409 shares of the company’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $224.25, for a total transaction of $1,437,218.25. Following the completion of the sale, the executive vice president now directly owns 20,232 shares in the company, valued at approximately $4,537,026. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 10,077 shares of company stock valued at $2,334,821. Corporate insiders own 1.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on CRL. JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating on the stock in a research note on Thursday, November 3rd. StockNews.com assumed coverage on shares of Charles River Laboratories International in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $250.00 to $241.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 3rd. Credit Suisse Group dropped their price objective on shares of Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday, November 3rd. Finally, Jefferies Financial Group upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Thursday, September 29th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $298.42.

Charles River Laboratories International Stock Up 2.8 %

CRL stock opened at $234.13 on Wednesday. The company has a market cap of $11.91 billion, a P/E ratio of 27.58, a P/E/G ratio of 1.38 and a beta of 1.29. Charles River Laboratories International, Inc. has a 52 week low of $181.36 and a 52 week high of $366.01. The company’s 50-day moving average price is $224.82 and its 200 day moving average price is $217.53. The company has a current ratio of 1.40, a quick ratio of 1.14 and a debt-to-equity ratio of 1.12.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its quarterly earnings data on Wednesday, November 2nd. The medical research company reported $2.63 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.12. The firm had revenue of $989.16 million for the quarter, compared to the consensus estimate of $978.65 million. Charles River Laboratories International had a net margin of 11.54% and a return on equity of 20.93%. On average, research analysts expect that Charles River Laboratories International, Inc. will post 10.88 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Articles

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.